BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2003
Reporting Context: The Company operates in three segments: Pharmaceuticals, Nutritionals, and Other Healthcare. The quarter was significantly impacted by the ongoing workdown of excess wholesaler inventories in the U.S. pharmaceutical business, the application of the consignment revenue model for certain wholesalers, and the resolution of major antitrust litigation settlements.

Key Financial Metrics

Note: Q1 2002 operating cash flow was negatively impacted by a $1,449 million tax payment related to the Clairol sale.

Material Changes vs. Prior Period

• Revenue: Net sales increased 1% to $4.711 billion. This growth was driven by a 3% increase in selling prices and a 3% favorable foreign exchange impact, offset by a 5% decrease in volume. International sales rose 15%, while domestic sales fell 6% due to generic competition and inventory workdowns.
• Profitability: Net earnings decreased 11% to $761 million. Earnings from continuing operations before taxes dropped 12% to $1.075 billion, primarily due to higher costs of products sold (product mix shift) and increased advertising/promotion spending.
• Segment Performance:
  • Pharmaceuticals: Sales up 2% to $3.906 billion; earnings down to $887 million. Domestic sales declined due to generic competition for GLUCOPHAGE*IR and TAXOL* and inventory workdowns for PLAVIX*.
  • Nutritionals: Sales down 4% to $433 million; earnings down to $69 million due to lower U.S. infant formula sales.
  • Other Healthcare: Sales up 2% to $372 million; earnings down to $54 million.
• Unusual Items:
  • 2003: Recorded a $21 million pre-tax gain from a vitamins litigation settlement. Incurred $12 million in restructuring charges and $14 million in other costs (asset impairments and accelerated depreciation).
  • 2002: Included a $90 million litigation settlement charge (BUSPAR), a $160 million in-process R&D charge (ImClone), and a $30 million gain on business sales.

Guidance, Outlook, and Risks

• Wholesaler Inventory: The Company expects the orderly workdown of excess pharmaceutical inventories held by U.S. wholesalers to be substantially complete by the end of 2003. Reported sales may not reflect underlying prescription demand due to these inventory fluctuations.
• Product Outlook:
  • PLAVIX*: Domestic prescription demand grew ~30% in Q1 2003 despite reported sales declines due to inventory workdowns. Full-year 2003 sales are expected to align with prescription growth.
  • ABILIFY*: Alliance revenue was $37 million; the product holds a 4% weekly new prescription share in the U.S. antipsychotic market.
  • GLUCOPHAGE*: FDA approved the 750 mg XR tablet in April 2003.
• Legal and Regulatory Risks:
  • Antitrust Settlements: Agreements in principle reached to settle TAXOL* ($135 million) and BUSPAR ($535 million) antitrust litigation. Full amounts were accrued in prior periods, but finalization requires court approval.
  • SEC/DOJ Investigations: Ongoing investigations into wholesaler inventory incentives, accounting reserves, and asset sales. Management believes all necessary restatement adjustments have been recorded.
  • ImClone: ImClone announced a potential restatement of financials regarding withholding tax liabilities. BMS recorded a $23 million net loss for its share of ImClone's losses in Q1 2003.
• Internal Controls: Management acknowledged two "material weaknesses" in internal controls identified by auditors regarding accounting and financial reporting, though they concluded disclosure controls were effective as of the evaluation date.

Investor Verification Checklist

• Inventory Workdown Progress: Verify the timeline and completion status of the U.S. wholesaler inventory workdown to assess future revenue normalization.
• Antitrust Settlement Finalization: Monitor court approvals for the TAXOL* and BUSPAR* settlements to ensure no additional liabilities arise.
• ImClone Restatement Impact: Track ImClone's final restated financials to determine if BMS needs to adjust its equity investment valuation or earnings.
• Generic Competition: Assess the long-term revenue impact of generic entry for GLUCOPHAGE*IR and TAXOL* on the Pharmaceuticals segment.
• Regulatory Investigations: Review updates on the SEC and DOJ investigations regarding accounting practices and wholesaler incentives.